Verley becomes first company to receive FDA "No Questions Letter" for functionalized dairy Proteins made via precision fermentation

Lyon, France – October 2025 – Verley, a French food biotechnology company pioneering functional dairy proteins through precision fermentation, has received the GRAS "No Questions Letter” from the U.S. Food and Drug Administration (FDA), officially confirming the safety of its ingredients for use in intended food applications. This official confirmation of ingredient safety marks a major regulatory milestone and clears the path for commercial launch in the U.S. market in 2026, the first step toward global expansion.
Verley is the first company globally to obtain a "No Questions Letter” from the FDA for dairy ingredients made via precision fermentation and enhanced with functionalization —a breakthrough that reinforces Verley's leadership in sustainable, high-performance protein innovation.
An FDA No Question Letter means that the administration has reviewed Verley's submission and has no further questions regarding the safety of the ingredient under the proposed conditions of use.
This letter confirms that the data provided was considered thorough and scientifically sound, enabling Verley to move forward with commercialization in the U.S.

The approval covers two of Verley’s flagship proteins:

• 🧪 FermWhey™ Native: A whey protein composed at 95% of β-lactoglobulin (BLG). Its clean amino acid profile is the same as conventional whey proteins with high leucine, supporting performance and recovery in sports and active nutrition
• 🧪 FermWhey™ MicroStab: A patented, microparticulated, functionalized protein designed to deliver superior thermal and pH stability in complex formulations such as ready-to-drink beverages.

"This is a major regulatory validation for our science and technology," said Hélène Briand, Co-founder and Chief Innovation & Commercial Officer at Verley. "Receiving the FDA’s 'No Questions' Letter is not only a milestone for Verley, it’s a signal that precision fermentation is ready to scale and complement conventional dairy, delivering nutritional performance with fewer resources."
This FDA milestone follows Verley’s self-affirmed GRAS designation in early 2025 and builds further confidence for U.S. customers, retailers, and manufacturers exploring advanced protein solutions.
Precision fermentation enables the production of pure, functional dairy proteins without relying on animals. Unlike “alternative proteins,” Verley’s proteins are designed to complement conventional dairy by expanding its functionality, improving sustainability, and meeting the evolving needs of modern consumers—including active lifestyles, GLP-1 users, and high-protein, low-sugar diets.

"This is just the beginning," added Stéphane Mac Millan, CEO of Verley. "With other geographies in motion and a growing demand for sustainable proteins, we’re proud to set a global benchmark in safety, performance, and trust.
And here’s something we’re especially proud of: We received this regulatory clearance just three years after founding the company, a testament to the clarity, speed, and execution of our scientific and commercial roadmap."
Verley continues to engage with regulators across other markets to expand its global footprint and enable a new generation of high-protein food products.

About Verley

Verley is a food biotech company based in France, creating high-purity, functionalized whey proteins through precision fermentation. By combining the best of dairy nutrition and biotechnological innovation, Verley helps food and beverage manufacturers develop next-generation products that meet the highest standards for taste, performance, and sustainability.

Press contact:

Thibaut Elijah Lafargue

Head of Marketing & Communication

lafargue.thibaut@gmail.com

+33 7 86 85 05 80

www.verley-food.com